News stories about Voyager Therapeutics (NASDAQ:VYGR) have trended somewhat positive this week, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Voyager Therapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media stories about the company an impact score of 44.114199406744 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Bernard Ravina Sells 3,630 Shares of Voyager Therapeutics Inc (VYGR) Stock (americanbankingnews.com)
- Voyager Therapeutics Inc (VYGR) Receives Average Recommendation of “Buy” from Brokerages (americanbankingnews.com)
- Voyager Therapeutics (VYGR) Rating Increased to Hold at Zacks Investment Research (americanbankingnews.com)
- Brokerages Expect Voyager Therapeutics Inc (VYGR) Will Post Quarterly Sales of $5.05 Million (americanbankingnews.com)
- Voyager Therapeutics (VYGR) Upgraded at BidaskClub (americanbankingnews.com)
Shares of Voyager Therapeutics (NASDAQ:VYGR) traded up $0.87 on Friday, hitting $18.27. The company had a trading volume of 314,400 shares, compared to its average volume of 311,837. Voyager Therapeutics has a 52-week low of $8.10 and a 52-week high of $25.99. The stock has a market capitalization of $468.92 and a PE ratio of -6.43.
VYGR has been the subject of a number of recent analyst reports. Stifel Nicolaus restated a “buy” rating and issued a $31.00 price objective (up from $20.00) on shares of Voyager Therapeutics in a research report on Monday, October 23rd. Canaccord Genuity initiated coverage on Voyager Therapeutics in a research report on Friday, October 27th. They set a “buy” rating and a $35.00 price target for the company. Zacks Investment Research cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 8th. Raymond James Financial initiated coverage on Voyager Therapeutics in a research report on Thursday, October 12th. They set an “outperform” rating and a $35.00 price target for the company. Finally, Cowen reiterated a “buy” rating on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $26.90.
In related news, insider Bernard Ravina sold 5,490 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $13.63, for a total transaction of $74,828.70. Following the completion of the sale, the insider now directly owns 10,983 shares in the company, valued at $149,698.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 14,610 shares of company stock valued at $207,158 over the last quarter. 8.00% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: This piece was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.thestockobserver.com/2018/01/12/voyager-therapeutics-vygr-receives-daily-news-sentiment-score-of-0-08.html.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.